The effect of improved metabolic risk factors and metformin therapy on circulating hepatokines in obese, insulin-resistant adolescents

Basit Öğe Kaydı
dc.authorid0000-0002-1044-6888
dc.contributor.authorKılınç, Suna
dc.contributor.authorKırankaya, Ayşegül
dc.contributor.authorAtay, Zeynep
dc.date.accessioned2019-12-27T06:06:07Z
dc.date.available2019-12-27T06:06:07Z
dc.date.issued2019
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractIntroduction: The molecular mechanisms underlying insulin resistance (IR) is complex and has not been fully elucidated yet. The experimental studies point out the role of liver-derived proteins, called hepatokines. Aims: To compare metabolic parameters and hepatokines levels in obese adolescents and healthy controls and to assess the effect of metformin therapy on plasma hepatokines levels in obese, insulin-resistant adolescents. Material and Methods: Sixty-nine subjects (38 girls, 31 boys) aged between 12-18 years were included. Participants were categorized into two groups. The first-group comprised obese adolescents with a body mass index (BMI) >95th percentile and the second-group comprised healthy controls with a BMI between the 5th and 85th percentile. Anthropometric and biochemical (glucose, insulin, lipid profile, Fetuin-A, fibroblast growth factor-21 (FGF-21), angiopoietin-related growth factor (AGF), leukocyte-derived chemotaxin 2 (LECT2) and Selenoprotein-P (SEPP1)) parameters were evaluated. Firstly, metabolic parameters and hepatokines levels were compared in obese group and healthy controls. Secondly all obese patients underwent a standard oral glucose tolerance test (OGTT). Patients diagnosed with IR at OGTT were started metformin (2g/day, 2 doses) therapy for 6-months. Then the differences in the biochemical characteristics and hepatokines levels analyzed between pre- and post-treatment. Plasma hepatokines levels were determined using an enzyme-linked immunosorbent assay (ELISA) method (Abbkine, Inc. China). Results: Study included 44 obese (21 males, 23 females; mean age: 13.1±1.9 years) and 25 healthy non-obese children (10 males, 15 females; mean age: 13.5±1.9 years). Glucose, insulin, HbA1c, Fetuin-A, LECT2 and SEPP1 levels were significantly higher in obese patients (P<0.05); FGF-21 and AGF levels were not significantly different between the two groups (P=0.776, P=0.214). There was a statistically significant decrease in serum glucose, insulin, HbA1c, total cholesterol, triglyceride and LECT2 levels and a statistically significant increase in serum HDL-cholesterol levels after 6-months of metformin therapy. There was no statistically significant difference in Fetuian-A, FGF-21, AGF and SEPP1 levels after treatment (P>0.05). Conclusion: Plasma levels of Fetuin-A, LECT2 and SEPP1, which are thought to be effective in insulin signaling pathways, were significantly higher in obese patients. Six-months of metformin therapy also found to be effective in decreasing serum LECT2 levels.
dc.identifier.citationKılınç, S., Kırankaya, A. ve Atay, Z. (2019). The effect of improved metabolic risk factors and metformin therapy on circulating hepatokines in obese, insulin-resistant adolescents. Hormone Research In Paediatrics içinde (157-157. ss.).
dc.identifier.endpage157
dc.identifier.issn1663-2818
dc.identifier.issn1663-2826
dc.identifier.issueSupplement: 1
dc.identifier.startpage157
dc.identifier.urihttps://hdl.handle.net/20.500.12511/4748
dc.identifier.volume91
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherKarger
dc.relation.ispartofHormone Research In Paediatricsen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectChildhood-Obesity
dc.subjectInsulin Resistance
dc.subjectMetformin
dc.subjectHepatokines
dc.subjectFetuin-A
dc.subjectEGF21
dc.subjectAGF,LECT2
dc.subjectSEPP1
dc.titleThe effect of improved metabolic risk factors and metformin therapy on circulating hepatokines in obese, insulin-resistant adolescents
dc.typeConference Object

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu